USA flag logo/image

An Official Website of the United States Government

Novel Nanofiltration Membranes for Isolation of Pharmaceutical Compounds

Award Information

Department of Health and Human Services
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
Solicitation Year:
Solicitation Topic Code:
Solicitation Number:
Small Business Information
335 WATER ST Wilmington, DE 19804-0000
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phase 1
Fiscal Year: 2011
Title: Novel Nanofiltration Membranes for Isolation of Pharmaceutical Compounds
Agency: HHS
Contract: 1R43RR032228-01
Award Amount: $399,912.00


DESCRIPTION (provided by applicant): Novel Nanofiltration Membranes for Isolation of Pharmaceutical Compounds Project Summary: In the chemical manufacturing of pharmaceutical compounds, organic syntheses are often carried out in organic solvents and involve intermediates and final products with high added value. These pharmaceutical active compounds having molecular weights in the range of 300-2000 g/mol are often thermally labile, and thermal separation processes such as distillation/thermal evaporation are not preferred. The broad objective of this program is to develop chemically-resistant nanofiltration membranes and membrane separation technology for isolation of these pharmaceutical compounds from organic solvents. In contrast to distillation, nanofiltration (NF) is a molecular level size-sieving based separation process and can be operated at ambient or sub-ambient temperatures. In NF, driven by the applied pressure gradient, low molecular weight compounds such as solvents permeate through nanofiltration membrane while retaining higher molecular weight compounds. Although nanofiltration technology for aqueous systems is well established, the technology for organic solvent-based systems is still under development because of the lack of highly chemicallyresistant nanofiltration membranes. Based on our experience with chemically resistant amorphous fluorine-based membranes and our recent ability to customize these membranes, Compact Membrane Systems, Inc. proposes to develop chemically-resistant organophilic NF membranes and hydrophilic NF membranes with superior membrane stability towards pharmaceutical solvents and chemicals, and superior membrane performance. Organophilic and hydrophilic custom amorphous fluorine-based polymers will be first synthesized, characterized and fabricated in to composite membranes. Then the composite membranes will be studied for NF performance with model solute-solvent systems. Hydrophilic solvent such as methanol will be used as model solvent to test the hydrophilic NF membranes. Similarly, toluene or hexane will be used as a model solvent to test organophilic NF membranes. Organophilic polymers and hydrophilic polymers will be further customized as necessary to achieve the desired NF characteristics (i.e. superior solvent flux and solute retention). After characterizing the NF membranes with model solute-solvent systems, they will be tested for isolation of active pharmaceutical ingredients and effect of various operating parameters on the NF membrane performance. PUBLIC HEALTH RELEVANCE: Unique nanofiltration membranes will be developed that are i) highly stable to the wide variety of process solvents used in the pharmaceutical manufacturing, ii) highly selective for drug intermediates and products by molecular weight, and iii) possessing high nanofiltration throughput for the wide range of drug industry solvents. This platform technology will be a widely desired and significant new tool for pharmaceutical manufacturing. The relevance to Public Health is lower cost medications, lower energy consumption, and less chemical pollution.

Principal Investigator:

Stuart Nemser

Business Contact:

Stuart Nemser
Small Business Information at Submission:

335 Water Street Newport, DE 19804-

EIN/Tax ID: 151034825
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No